Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir

ABSTRACT In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorporation (CONITEC). However, these medicines...

Full description

Bibliographic Details
Main Authors: Lenyta Oliveira Gomes, Marina Rodrigues Teixeira, Júnior André da Rosa, Alberi Adolfo Feltrin, João Paulo V. Rodrigues, Mariane D’Avila Vecchi, Jane Meire M. Carneiro, Lúcia de Araújo C. B. Noblat, Silvana Gama F. Chachá, Ana de Lourdes C. Martinelli, Leonardo Regis L. Pereira, Marysabel Pinto T. Silveira, Carine Raquel Blatt, Mareni Rocha Farias
Format: Article
Language:English
Published: Universidade de São Paulo 2018-06-01
Series:Revista do Instituto de Medicina Tropical de São Paulo
Subjects:
Chronic hepatitis C treatment
Protease inhibitors
High cost medicines
Real life studies
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652018005000217&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652018005000217&lng=en&tlng=en

Similar Items